Clinical Trials

Phase 3 Clinical Trials

Image Description
Samantha Trolli

Published 08 Dec 2022 - Updated 08 Dec 2022

Phase 3 Clinical Trials - Infiuss Health


Vaccine development takes time and careful study.

It takes time and careful study to develop a vaccine. It's not a matter of getting together some ingredients, mixing them up, and giving it to someone to see how it works. Vaccine trials are very important, because they need to be done carefully in order to make sure the vaccine is safe and effective.

Vaccines are developed in phases: first they are tested on animals; then they move on to Phase 1 human clinical trials where they're given to healthy people; then Phase 2 trials involve giving the vaccine to larger groups of people who have been diagnosed with specific diseases; finally, Phase 3 clinical trials test whether or not this new treatment works as expected—and if so, those results can be used by healthcare providers around the world in order make recommendations about which vaccines should be used by their patients going forward. 

What is a phase 3 clinical trial?

Phase 3 clinical trials are the final step before a drug or treatment is approved by the Food and Drug Administration (FDA). These trials test the safety and efficacy of a drug or treatment by comparing it to an already existing medication or treatment. Phase 3 clinical trials typically involve hundreds of participants and often last for years. While phase 2 trials help researchers determine whether a drug is safe for humans, phase 3 trials focus on determining whether it works.

Phase 3 studies have many participants to provide statistically relevant results. In addition, they follow strict protocols in order to ensure that all participants undergo similar procedures and receive identical treatments, if applicable. This helps researchers compare different treatments more easily when analyzing data from any given study participant's results against others who may have received different treatments during the trial.

Are phase 3 trials randomized?

Yes, phase 3 trials are randomized. Randomization helps to ensure that the groups in the study are balanced and comparable, and that any differences in outcome are due to the intervention being tested. This is important because it means that patients are less likely to be treated differently during the course of a trial or between trials.

The basic design for a phase 3 clinical trial is somewhat like the design for Phase 1 and Phase 2 clinical trials, with a control group and a test group.

The basic design for a phase 3 clinical trial is somewhat like the design for Phase 1 and Phase 2 clinical trials, with a control group and a test group. The test group receives the medication being tested, while the control group receives either no treatment (the placebo) or some other treatment. For example, if the test medication is an injection, the control group might receive a placebo, such as saline. Both groups are assigned at random to receive their respective treatments. This way, neither the participants nor researchers know which condition is superior or inferior to another.

The duration of a phase 3 study depends on how long it takes to collect enough data from patients who have been given both types of medications in order to make conclusions about which one is more effective or safer than another. In general, though, most phase 3 studies last for two years; this allows researchers enough time to conduct their research but does not delay patients too long from receiving effective therapies if necessary

Phase 3 clinical trials may have thousands of participants to provide statistically relevant results.

Phase 3 trials are usually large and involve a larger number of participants than phase 1 or 2 trials. The goal is to provide statistically relevant results, which means that the number of participants must be large enough to accurately represent the population being tested on. This is why phase 3 clinical trials can have thousands of people involved in them.

Phase 3 clinical trials may have thousands of participants to provide statistically relevant results. This is important because the larger the number of participants, the more statistically relevant the results. And it’s that statistical relevance that makes a medication or treatment more likely to be approved by the FDA.

The goal of Phase 3 clinical trials is “evidence based” findings, showing that your treatment works better than other treatments available for your specific condition or illness and is safe for use by people like you.

The FDA must approve phase 3 clinical trials.

Phase 3 clinical trials are the final phase of drug testing before a new medication is approved by the U.S. Food and Drug Administration (FDA). The FDA must approve phase 3 clinical trials before a medication can be marketed in the United States, so this step takes a lot of time and effort to complete.

The FDA's Center for Drug Evaluation and Research (CDER) is responsible for reviewing new drug applications that come from pharmaceutical companies as well as reviewing products already on the market that may have been recalled or altered in some way. CDER also oversees prescription drugs, over-the-counter medications, biologics such as vaccines and blood products and medical devices such as artificial hips or pacemakers.

How long does it take to complete a Phase 3 clinical trial?

A Phase 3 trial can take years to complete. One of the reasons for this is that it can take a long time to recruit enough people who will participate in the study, especially if you are testing a new and unproven treatment. Additionally, once you have recruited your participants, it will take time to test their responses and gather data on whether or not they experienced side effects and other health conditions during the study period.

After gathering all this data, researchers must analyze it and determine whether there is sufficient evidence that supports their hypothesis. If not enough people responded favorably to your drug or device (or if too many experienced negative health consequences), then there isn’t enough evidence available yet for FDA approval of your drug or device—and you’ll need more studies done before Phase 3 is able to end. 

Who can I contact for more information on Phase 3 trials and participant recruitment? 

If you are interested in participating in a Phase 3 clinical trial and would like more information, contact your local hospital or university. They may be conducting Phase 3 trials on their own or know of others that are accepting participants. You can also contact a local drug company that is conducting research for new medications. Another option would be to reach out to your local health clinic, as many clinics will offer services such as blood work and cancer screenings at no cost or at reduced rates if you are willing to participate in certain studies related to disease prevention and treatment. Lastly, reach out to us at Infiuss Health and request to become a potential participant. 

Find new health insights

Infiuss Health insights contains inspiring thought leadership on health issues and the future of health data management and new research.